The Delta variant has become the dominant strain of SARS-CoV-2. We summarised the evidence on COVID-19 vaccine effectiveness (VE) identified in 17 studies that investigated VE against different endpoints. Pooled VE was 63.1% (95% confidence interval (CI): 40.9–76.9) against asymptomatic infection, 75.7% (95% CI: 69.3–80.8) against symptomatic infection and 90.9% (95% CI: 84.5–94.7) against hospitalisation. Compared with the Alpha variant, VE against mild outcomes was reduced by 10–20%, but fully maintained against severe COVID-19.
All Keywords
【저자키워드】 COVID-19, SARS-CoV-2, vaccination, systematic review, delta variant, variant of concern, vaccine effectiveness, 【초록키워드】 COVID-19 vaccine, severe COVID-19, outcome, delta variant, asymptomatic infection, Effectiveness, Mild, Alpha, Alpha variant, hospitalisation, symptomatic infection, Evidence, endpoints, 95% CI, 95% confidence interval, dominant, investigated, was reduced, 【제목키워드】 Meta-analysis, COVID-19 vaccine, SARS-COV-2 infection, Delta, B.1.617.2,
【저자키워드】 COVID-19, SARS-CoV-2, vaccination, systematic review, delta variant, variant of concern, vaccine effectiveness, 【초록키워드】 COVID-19 vaccine, severe COVID-19, outcome, delta variant, asymptomatic infection, Effectiveness, Mild, Alpha, Alpha variant, hospitalisation, symptomatic infection, Evidence, endpoints, 95% CI, 95% confidence interval, dominant, investigated, was reduced, 【제목키워드】 Meta-analysis, COVID-19 vaccine, SARS-COV-2 infection, Delta, B.1.617.2,
Delta 변종은 SARS-CoV-2의 지배적인 변종이 되었습니다. 우리는 다양한 종점에 대해 VE를 조사한 17개 연구에서 확인된 COVID-19 백신 효과(VE)에 대한 증거를 요약했습니다. 통합 VE는 무증상 감염에 대해 63.1%(95% 신뢰 구간(CI): 40.9–76.9), 증상 감염에 대해 75.7%(95% CI: 69.3–80.8), 입원에 대해 90.9%(95% CI: 84.5–94.7)였습니다. . Alpha 변이체와 비교하여 경미한 결과에 대한 VE는 10-20% 감소했지만 심각한 COVID-19에 대해서는 완전히 유지되었습니다.